CYTOKINETICS, INCORPORATED Earnings Per Share (Diluted)
CYTOKINETICS, INCORPORATED (CYTK) reported Earnings Per Share (Diluted) of -$1.50 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED earnings per share, diluted for the quarter ending 2026-06-30 was -$1.50.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for the quarter ending 2026-03-31 was -$1.67.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for the quarter ending 2025-12-31 was -$1494.61.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for the quarter ending 2025-09-30 was -$2.55.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for fiscal 2025 was -$6.54.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for fiscal 2024 was -$5.26.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for fiscal 2023 was -$5.45.
- CYTOKINETICS, INCORPORATED earnings per share, diluted for fiscal 2022 was -$4.33.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.50 10-Q · filed 2026-08-06 | -$3.17 10-Q · filed 2026-08-06 | -$4667.49 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$7183.60 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2026-03-31 | -$1.67 10-Q · filed 2026-05-05 | -$3166.53 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$5703.11 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$6839.70 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2025-12-31 | -$1494.61 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$4035.66 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$5169.21 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$6.54 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$2.55 10-Q · filed 2025-11-05 | -$3679.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$5.04 10-Q · filed 2025-11-05 | -$6318.13 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2025-06-30 | -$1.12 10-Q · filed 2026-08-06 | -$2.49 10-Q · filed 2026-08-06 | -$3755.68 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$5119.16 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2025-03-31 | -$1.36 10-Q · filed 2026-05-05 | -$2632.08 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3996.10 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$5309.21 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2024-12-31 | -$1270.06 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2634.08 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$3946.29 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$5.26 10-K · filed 2026-02-26 | ||
| 2024-09-30 | -$1.36 10-Q · filed 2025-11-05 | -$2678.09 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$4.00 10-Q · filed 2025-11-05 | -$5387.60 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2024-06-30 | -$1.31 10-Q · filed 2025-08-07 | -$2.63 10-Q · filed 2025-08-07 | -$4021.02 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$5367.80 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2024-03-31 | -$1.33 10-Q · filed 2025-05-06 | -$2711.53 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$4058.94 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$5402.58 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2023-12-31 | -$1381.42 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2729.10 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$4072.76 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$5.45 10-K · filed 2026-02-26 | ||
| 2023-09-30 | -$1.35 10-Q · filed 2024-11-07 | -$2690.55 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$4.07 10-Q · filed 2024-11-07 | -$5519.74 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2023-06-30 | -$1.34 10-Q · filed 2024-08-09 | -$2.72 10-Q · filed 2024-08-09 | -$4172.89 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$5689.27 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2023-03-31 | -$1.38 10-Q · filed 2024-05-10 | -$2829.90 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$4346.88 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$4665.26 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2022-12-31 | -$1450.46 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2967.96 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$3276.87 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$4.33 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$1.52 10-Q · filed 2023-11-03 | -$1806.57 derived: net income ÷ weighted average shares · filed 2023-11-03 | -$2.85 10-Q · filed 2023-11-03 | -$3237.01 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2022-06-30 | -$0.23 10-Q · filed 2023-08-03 | -$1.28 10-Q · filed 2023-08-03 | -$1645.82 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2576.47 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2022-03-31 | -$1.05 10-Q · filed 2023-05-05 | -$1418.95 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2358.03 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$3208.23 derived: net income ÷ weighted average shares · filed 2026-04-17 | ||
| 2021-12-31 | -$363.22 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$1296.78 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2136.03 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$2.80 10-K · filed 2024-02-28 | ||
| 2021-09-30 | -$0.95 10-Q · filed 2022-11-04 | -$1810.06 derived: net income ÷ weighted average shares · filed 2022-11-04 | -$2.48 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | -$0.86 10-Q · filed 2022-08-05 | -$1.52 10-Q · filed 2022-08-05 | ||||
| 2020-12-31 | -$1.97 10-K · filed 2023-03-01 | |||||
| 2017-12-31 | -$0.75 derived: net income ÷ weighted average shares · filed 2018-03-05 | -$1.35 derived: net income ÷ weighted average shares · filed 2018-11-09 | -$2.59 10-K · filed 2018-03-05 | |||
| 2017-09-30 | -$0.60 10-Q · filed 2017-11-03 | -$1.82 10-Q · filed 2017-11-03 | ||||
| 2016-12-31 | $0.16 10-K · filed 2018-03-05 | $0.93 derived: net income ÷ weighted average shares · filed 2018-03-05 | $0.39 10-K · filed 2018-03-05 | |||
| 2016-09-30 | $0.77 10-K · filed 2018-03-05 | $0.74 10-Q · filed 2016-11-03 | $0.22 10-Q · filed 2017-11-03 | $0.19 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | -$0.29 10-K · filed 2018-03-05 | |||||
| 2016-03-31 | -$0.31 10-K · filed 2018-03-05 | |||||
| 2015-12-31 | -$0.24 derived: net income ÷ weighted average shares · filed 2018-03-05 | -$0.46 derived: net income ÷ weighted average shares · filed 2018-03-05 | -$0.97 10-K · filed 2018-03-05 | |||
| 2015-09-30 | -$0.23 10-Q/A · filed 2016-12-15 | -$0.73 10-Q/A · filed 2016-12-15 | ||||
| 2014-12-31 | -$0.41 10-K · filed 2017-03-06 | |||||
| 2011-12-31 | -$0.72 10-K · filed 2012-03-13 | |||||
| 2010-12-31 | -$0.77 10-K · filed 2012-03-13 | |||||
| 2009-12-31 | $0.42 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |